A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents
International Journal of Molecular Sciences, 2023 Several reviews of inhibitors of topoisomerase II have been published, covering research before 2018. Therefore, this review is focused primarily on more recent publications with relevant points from the earlier literature.
Cosmas O. Okoro, T. Fatoki
semanticscholar +2 more sources
Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors. [PDF]
J Virol, 2019 Patients afflicted by triple-negative breast cancer have decreased survival and limited therapeutic options. Reovirus infection results in cell death of a variety of cancers, but it is unknown if different reovirus types lead to triple-negative breast ...
Rodríguez Stewart RM +9 more
europepmc +2 more sources
Discovery of potent bisindole-based pyrazolopyridine derivatives as topoisomerase inhibitors: DNA damage induction and synergistic antileukemic activity [PDF]
Frontiers in PharmacologyIntroductionThe development of novel anticancer agents targeting DNA replication and repair mechanisms remains a priority in leukemia therapy. In this study, newly synthesized derivatives incorporating bis-indole and pyrazolo[3,4-b]pyridine scaffolds ...
Wagdy M. Eldehna +12 more
doaj +2 more sources
DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion.
J Mol Biol, 2019 Type II topoisomerases regulate DNA topology by making a double-stranded break in one DNA duplex, transporting another DNA segment through this break and then resealing it.
Bax BD, Murshudov G, Maxwell A, Germe T.
europepmc +2 more sources
Topoisomerase inhibitors promote cancer cell motility via ROS-mediated activation of JAK2-STAT1-CXCL1 pathway. [PDF]
J Exp Clin Cancer Res, 2019 Topoisomerase inhibitors (TI) can inhibit cell proliferation by preventing DNA replication, stimulating DNA damage and inducing cell cycle arrest. Although these agents have been commonly used in the chemotherapy for the anti-proliferative effect, their ...
Liu J, Qu L, Meng L, Shou C.
europepmc +2 more sources
Mechanism-informed identification of FDA-approved topoisomerase inhibitors disrupting SARS-CoV-2 nucleocapsid–RNA interactions [PDF]
BMC ChemistrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein (NP) interaction with viral RNA is vital for viral replication and immune evasion, making it an attractive target for antiviral development.
Da-Wei Zhang +5 more
doaj +2 more sources
Topoisomerase II as a Novel Antiviral Target against Panarenaviral Diseases
Viruses, 2022 Although many arenaviruses cause severe diseases with high fatality rates each year, treatment options are limited to off-label use of ribavirin, and a Food and Drug Administration (FDA)-approved vaccine is not available.
Tosin Oladipo Afowowe +4 more
doaj +1 more source
Inhibition of Zn(II) binding type IA topoisomerases by organomercury compounds and Hg(II). [PDF]
PLoS ONE, 2015 Type IA topoisomerase activities are essential for resolving DNA topological barriers via an enzyme-mediated transient single strand DNA break. Accumulation of topoisomerase DNA cleavage product can lead to cell death or genomic rearrangement.
Bokun Cheng +4 more
doaj +1 more source
The DNA-topoisomerase Inhibitors in Cancer Therapy
Biomedical & Pharmacology Journal, 2022 DNA-topoisomerases are ubiquitous enzymes essential for major cellular processes. In recent years, interest in DNA-topoisomerases has increased not only because of their crucial role in promoting DNA replication and transcription processes, but also ...
S. Mastrangelo +5 more
semanticscholar +1 more source
Journal of Medicinal Chemistry, 2021 Novel bacterial topoisomerase inhibitors (NBTIs) are among the most promising new antibiotics in preclinical/clinical development. We previously reported dioxane-linked NBTIs with potent antistaphylococcal activity and reduced hERG inhibition, a key ...
Yanran Lu +20 more
semanticscholar +1 more source